Dr. Dima Youssef, MD

Dr. Youssef practices at Spring Valley Hospital Medical Center in Las Vegas, Nevada, part of Universal Health Services.

Dr. Youssef's NPI, 1891189148, was assigned on March 25, 2015. Dr. Youssef holds Michigan license 4301108110.

Dr. Youssef's primary practice is Spring Valley Hospital Medical Center, at 5400 South Rainbow Blvd, Las Vegas, NV 89118 in Clark County. The practice phone is (702) 853-3000.

Dr. Youssef's primary practice is Spring Valley Hospital Medical Center in Las Vegas, Nevada, part of Universal Health Services. Dr. Youssef is also affiliated with Valley Hospital Medical Center. The medical group on file is APEX Infectious Disease of Nevada. Dmand AI also links Dr. Youssef to 4 more hospitals, 2 group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Youssef practices, 9 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Youssef's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Youssef is licensed in Michigan.

CMS data shows 3,678 Medicare services from Dr. Youssef across 4 procedure codes in 2024, for 471 Medicare patients. Medicare paid $274,612 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 471 Medicare patients who saw Dr. Youssef in 2024. The largest group is 65 to 74, with 159 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Youssef's median patient age at 71, with 53% women.

In 2024, Dr. Youssef wrote 200 Medicare Part D claims for 58 patients. 97% of them were for generic drugs. CMS names the drug for 154 of them, across 5 drugs with 11 or more claims each, at $37,695 in total drug cost. In 2023, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Youssef for performance year 2024, reported as part of a group. Dr. Youssef accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Youssef as offering telehealth.

Dmand AI links 60 papers to Dr. Youssef, published from 2011 to 2025. 2019 was the busiest year, with 6. The most frequent topics are Sepsis, MicroRNAs and Myeloid-Derived Suppressor Cells. Dr. Youssef has published most often in Cureus. Dr. Youssef's most frequent co-authors are Charles Emory Mccall, MD, Beth Ann Bailey, MD and Tariq S. Marroush, MD.

CMS Open Payments shows 21 general payments to Dr. Youssef from 9 drug and device companies from 2019 to 2024. Food and beverage make up the largest share, 100% of the total. Melinta Therapeutics, Inc. paid the most, $353.